Gene Expression Profiles in Primary Sjögren's Syndrome With and Without Systemic Manifestations. Issue 10 (21st October 2019)

• Record Type: Journal Article
• Authors: Vitali, Claudio; Dolcino, Marzia; Del Papa, Nicoletta; Minniti, Antonina; Pignataro, Francesca; Maglione, Wanda; Lunardi, Claudio; Puccetti, Antonio
• Is Part Of: ACR open rheumatology. Volume 1:Issue 10(2019)
• Page Start: 603
• Page End: 613
• Publication Date: 2019-10-21
• Subjects: Rheumatology -- Periodicals; 616.723005
• DOI: 10.1002/acr2.11082
• Languages: English
• ISSNs: 2578-5745

Abstract

Abstract : Objective: To investigate the gene expression profile in patients with Sjögren's syndrome that is characterized by different clinical phenotypes. Methods: RNA from peripheral blood mononuclear cells was purified in 8 patients with glandular features (GFs) and widespread pain (WP) and 11 with extraglandular manifestations (EGMs) and then was analyzed by hybridization on a human gene chip exploring more than 40, 000 human genes. Differentially expressed genes (DEGs) in the two subgroups (ie, those with false discovery rate–corrected P values ≤ 0.01) with respect to 20 healthy controls have been submitted to functional classification using a Gene Ontology database and were mapped to define the networks of protein to protein interactions (PPIs). Results: The enriched pathway analyses of DEGs and of the highly interconnected modules identified in the PPI networks showed that the pathological processes characterizing the two subgroups were substantially different. The predominant pathways in patients with EGMs are related to T‐ and B‐cell activation, Toll‐like receptor, interferon signaling, and apoptosis. Conversely, pathological processes related to pain transmission and modulation are preferentially operative in patients with GFs and WP. These data suggest that a neuroinflammatory pathway driven by cytokines and chemokines may play a central role in triggering WP features in this phenotype of patients. Conclusion: The present study supports the hypothesis that different biological pathways are operative in patients with primary Sjögren's syndrome with different clinical phenotypes. A better knowledge of these specific processes might help in tailoring more effective target therapies.